https://www.businessline.global/aptorum-group-announces-submission-of-clinical-trial-application-for-als-4-an-orally-administered-small-molecule-drug-for-the-treatment-of-infections-caused-by-staphylococcus-aureus-including-methici/press-release/
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)